Pemphigus Clinical Trial
Official title:
Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid
The primary objective of this study is to describe and compare plasmatic anti-proteasome auto-antibody concentrations among three distinct groups: (1) patients suffering from bullous pemphigoide; (2) patients suffering from other dermatological auto-immune diseases; (3) an elderly control group.
The secondary objectives of this study are:
To compare the following parameters between the 3 groups:
- plasmatic proteasome concentrations
- plasmatic proteasome proteolytic activity
To explore the potential relationships between:
- plasmatic proteasome concentrations
- plasmatic proteasome proteolytic activity
- plasmatic anti-proteasome auto-antibody concentrations
- measures of disease severity for dermatological auto-immune diseases
To characterize plasmatic anti-proteasome auto-antibodies in patients suffering from bullous
pemphigoide and other dermatological auto-immune diseases (other bullous auto immune
diseases: pemphigus, cutaneous lupus, ...).
To characterize the expression and the activity of proteasomes in skin samples, in plasma and
in circulating mononuclear cells in patients with bullous pemphigoide.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05534776 -
Validation of 5-Point Investigator Global Assessments for Pemphigus
|
||
| Terminated |
NCT00278642 -
Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders
|
Phase 1 | |
| Not yet recruiting |
NCT05898308 -
Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus
|
Phase 4 | |
| Active, not recruiting |
NCT01974518 -
Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus
|
Phase 3 | |
| Recruiting |
NCT05284929 -
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
|
||
| Recruiting |
NCT05954416 -
FARD (RaDiCo Cohort) (RaDiCo-FARD)
|
||
| Completed |
NCT00283712 -
Use of Infliximab for the Treatment of Pemphigus Vulgaris
|
Phase 2 | |
| Not yet recruiting |
NCT06285435 -
Coagulation Activation in Patients With Pemphigus
|
||
| Completed |
NCT01299857 -
Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab
|
Phase 3 | |
| Completed |
NCT00960713 -
The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders
|
N/A | |
| Completed |
NCT00213512 -
Effect of Anti CD20 in Pemphigus Desease
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT04400994 -
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus
|
Phase 2 | |
| Recruiting |
NCT02237313 -
Identification of Vulnerability Factors in the Course of Pemphigus Patients
|
N/A | |
| Terminated |
NCT03075904 -
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
|
Phase 1/Phase 2 | |
| Terminated |
NCT03762265 -
A Study of PRN1008 in Patients With Pemphigus
|
Phase 3 | |
| Recruiting |
NCT02365675 -
Wound Dressings for Pemphigus and Pemphigoid
|
N/A | |
| Recruiting |
NCT01338103 -
Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex
|
N/A | |
| Active, not recruiting |
NCT00656656 -
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
|
Phase 2 | |
| Completed |
NCT00127764 -
European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus
|
Phase 2/Phase 3 | |
| Recruiting |
NCT01313923 -
Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus
|
Phase 0 |